Our study showed that anti-angiogenetic agents can improve the PFS in ovarian cancer regardless of the treatment setting or type of drug used (VEGF inhibitors, VEGF-R inhibitors or angiopoietin inhibitors), thus being an option in the treatment of ovarian cancer. Here, KDR is linked to ovarian cancer.